Figure 2.
VWF binding to myosin inhibited by anti-A1 domain antibodies and collagen. VWF binding to myosin was measured with or without the addition of anti-VWF antibodies or collagen. The y-axis shows the percentage of VWF bound to myosin compared with a sample with VWF and no inhibitor. AVW3 is an anti-VWF A1 domain antibody. AVW5 is also an anti-VWF antibody, but it is located outside of the A1 domain. DAKO is a polyclonal anti-VWF antibody. AP2 is an anti-platelet αIIbβ3 antibody added as a negative control. Collagen IV (COL4) and collagen III (COL3) were also added as potential inhibitors. Error bars denote 1 standard deviation. n ≥ 3 for each experiment. **P < .005 vs control plasma (Plasma).

VWF binding to myosin inhibited by anti-A1 domain antibodies and collagen. VWF binding to myosin was measured with or without the addition of anti-VWF antibodies or collagen. The y-axis shows the percentage of VWF bound to myosin compared with a sample with VWF and no inhibitor. AVW3 is an anti-VWF A1 domain antibody. AVW5 is also an anti-VWF antibody, but it is located outside of the A1 domain. DAKO is a polyclonal anti-VWF antibody. AP2 is an anti-platelet αIIbβ3 antibody added as a negative control. Collagen IV (COL4) and collagen III (COL3) were also added as potential inhibitors. Error bars denote 1 standard deviation. n ≥ 3 for each experiment. **P < .005 vs control plasma (Plasma).

Close Modal

or Create an Account

Close Modal
Close Modal